Allogeneic Stem Cell Transplantation for Blast Crisis Chronic
Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A
Retrospective Study by the EBMT Chronic Malignancies Working
Party

J 2019

Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party

RADUJKOVIC, Aleksandar, Sascha DIETRICH, Henric-Jan BLOK, Arnon NAGLER, Francis AYUK et. al.

Základní údaje

Originální název

Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party

Autoři

RADUJKOVIC, Aleksandar (276 Německo, garant), Sascha DIETRICH (276 Německo), Henric-Jan BLOK (528 Nizozemské království), Arnon NAGLER (376 Izrael), Francis AYUK (276 Německo), Juergen FINKE (276 Německo), Johanna TISCHER (276 Německo), Jiří MAYER (203 Česká republika, domácí), Yener KOC (792 Turecko), Federica SORA (380 Itálie), Jakob PASSWEG (756 Švýcarsko), Jenny L. BYRNE (826 Velká Británie a Severní Irsko), Pavel JINDRA (203 Česká republika), Joan Hendrik VEELKEN (528 Nizozemské království), Gerard SOCIE (250 Francie), Johan MAERTENS (56 Belgie), Nicolaas SCHAAP (528 Nizozemské království), Michael STADLER (276 Německo), Maija ITALA-REMES (246 Finsko), Eleni THOLOULI (826 Velká Británie a Severní Irsko), Mutlu ARAT (792 Turecko), Vanderson ROCHA (76 Brazílie), Per LJUNGMAN (752 Švédsko), Ibrahim YAKOUB-AGHA (250 Francie), Nicolaus KROGER (276 Německo) a Yves CHALANDON (756 Švýcarsko)

Vydání

Biology of Blood and Marrow Transplantation, New York, Elsevier Science INC, 2019, 1083-8791

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.853

Kód RIV

RIV/00216224:14110/19:00112124

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.bbmt.2019.06.028

UT WoS

000492801700013

Klíčová slova anglicky

Chronic myeloid leukemia; Allogeneic stem cell; transplantation; Outcome; Blast crisis; Tyrosine kinase inhibitor

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 11. 3. 2020 14:14, Mgr. Tereza Miškechová

Anotace

V originále

The prognosis of patients with blast crisis (BC) chronic myeloid leukemia (CML) is still dismal. Allogeneic stem cell transplantation represents the only curative treatment option, but data on transplant outcomes are scarce. We therefore conducted a retrospective, registry-based study of adult patients allografted for BC CML, focusing on patients with active disease at transplant and pretransplant prognostic factors. One hundred seventy patients allografted for BC CML after tyrosine kinase inhibitor pretreatment between 2004 and 2016 were analyzed. Before transplant, 95 patients were in remission, whereas 75 patients had active BC. In multivariable analysis of the entire cohort, active BC at transplant was the strongest factor associated with decreased overall survival (hazrd ratio, 1.87; P = .010) and shorter leukemia-free survival (LFS; hazard ratio, 1.69; P= .017). For patients with BC in remission at transplant, advanced age (>= 45 years), lower performance status (<= 80%), longer interval from diagnosis BC to transplant (>12 months), myeloablative conditioning, and unrelated donor (UD) transplant were risk factors for inferior survival. In patients with active BC, only UD transplant was significantly associated with prolonged LFS and trended toward improved overall survival. In summary, survival of patients allografted for BC CML was strongly dependent on pretransplant remission status. In patients with remission of BC, conventional prognostic factors remained the major determinants of outcome, whereas in those with active BC at transplant, UD transplant was associated with prolonged LFS in our study. (C) 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.

Citovat

RADUJKOVIC, Aleksandar, Sascha DIETRICH, Henric-Jan BLOK, Arnon NAGLER, Francis AYUK, Juergen FINKE, Johanna TISCHER, Jiří MAYER, Yener KOC, Federica SORA, Jakob PASSWEG, Jenny L. BYRNE, Pavel JINDRA, Joan Hendrik VEELKEN, Gerard SOCIE, Johan MAERTENS, Nicolaas SCHAAP, Michael STADLER, Maija ITALA-REMES, Eleni THOLOULI, Mutlu ARAT, Vanderson ROCHA, Per LJUNGMAN, Ibrahim YAKOUB-AGHA, Nicolaus KROGER a Yves CHALANDON. Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party. Biology of Blood and Marrow Transplantation. New York: Elsevier Science INC, 2019, roč. 25, č. 10, s. 2008-2016. ISSN 1083-8791. Dostupné z: https://dx.doi.org/10.1016/j.bbmt.2019.06.028.

@article{1600359,
   author = {Radujkovic, Aleksandar and Dietrich, Sascha and Blok, HenricandJan and Nagler, Arnon and Ayuk, Francis and Finke, Juergen and Tischer, Johanna and Mayer, Jiří and Koc, Yener and Sora, Federica and Passweg, Jakob and Byrne, Jenny L. and Jindra, Pavel and Veelken, Joan Hendrik and Socie, Gerard and Maertens, Johan and Schaap, Nicolaas and Stadler, Michael and ItalaandRemes, Maija and Tholouli, Eleni and Arat, Mutlu and Rocha, Vanderson and Ljungman, Per and YakoubandAgha, Ibrahim and Kroger, Nicolaus and Chalandon, Yves},
   article_location = {New York},
   article_number = {10},
   doi = {http://dx.doi.org/10.1016/j.bbmt.2019.06.028},
   keywords = {Chronic myeloid leukemia; Allogeneic stem cell; transplantation; Outcome; Blast crisis; Tyrosine kinase inhibitor},
   language = {eng},
   issn = {1083-8791},
   journal = {Biology of Blood and Marrow Transplantation},
   title = {Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party},
   url = {http://dx.doi.org/10.1016/j.bbmt.2019.06.028},
   volume = {25},
   year = {2019}
}

TY  - JOUR
ID  - 1600359
AU  - Radujkovic, Aleksandar - Dietrich, Sascha - Blok, Henric-Jan - Nagler, Arnon - Ayuk, Francis - Finke, Juergen - Tischer, Johanna - Mayer, Jiří - Koc, Yener - Sora, Federica - Passweg, Jakob - Byrne, Jenny L. - Jindra, Pavel - Veelken, Joan Hendrik - Socie, Gerard - Maertens, Johan - Schaap, Nicolaas - Stadler, Michael - Itala-Remes, Maija - Tholouli, Eleni - Arat, Mutlu - Rocha, Vanderson - Ljungman, Per - Yakoub-Agha, Ibrahim - Kroger, Nicolaus - Chalandon, Yves
PY  - 2019
TI  - Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party
JF  - Biology of Blood and Marrow Transplantation
VL  - 25
IS  - 10
SP  - 2008-2016
EP  - 2008-2016
PB  - Elsevier Science INC
SN  - 10838791
KW  - Chronic myeloid leukemia
KW  - Allogeneic stem cell
KW  - transplantation
KW  - Outcome
KW  - Blast crisis
KW  - Tyrosine kinase inhibitor
UR  - http://dx.doi.org/10.1016/j.bbmt.2019.06.028
L2  - http://dx.doi.org/10.1016/j.bbmt.2019.06.028
N2  - The prognosis of patients with blast crisis (BC) chronic myeloid leukemia (CML) is still dismal. Allogeneic stem cell transplantation represents the only curative treatment option, but data on transplant outcomes are scarce. We therefore conducted a retrospective, registry-based study of adult patients allografted for BC CML, focusing on patients with active disease at transplant and pretransplant prognostic factors. One hundred seventy patients allografted for BC CML after tyrosine kinase inhibitor pretreatment between 2004 and 2016 were analyzed. Before transplant, 95 patients were in remission, whereas 75 patients had active BC. In multivariable analysis of the entire cohort, active BC at transplant was the strongest factor associated with decreased overall survival (hazrd ratio, 1.87; P = .010) and shorter leukemia-free survival (LFS; hazard ratio, 1.69; P= .017). For patients with BC in remission at transplant, advanced age (>= 45 years), lower performance status (<= 80%), longer interval from diagnosis BC to transplant (>12 months), myeloablative conditioning, and unrelated donor (UD) transplant were risk factors for inferior survival. In patients with active BC, only UD transplant was significantly associated with prolonged LFS and trended toward improved overall survival. In summary, survival of patients allografted for BC CML was strongly dependent on pretransplant remission status. In patients with remission of BC, conventional prognostic factors remained the major determinants of outcome, whereas in those with active BC at transplant, UD transplant was associated with prolonged LFS in our study. (C) 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.
ER  -

RADUJKOVIC, Aleksandar, Sascha DIETRICH, Henric-Jan BLOK, Arnon NAGLER, Francis AYUK, Juergen FINKE, Johanna TISCHER, Jiří MAYER, Yener KOC, Federica SORA, Jakob PASSWEG, Jenny L. BYRNE, Pavel JINDRA, Joan Hendrik VEELKEN, Gerard SOCIE, Johan MAERTENS, Nicolaas SCHAAP, Michael STADLER, Maija ITALA-REMES, Eleni THOLOULI, Mutlu ARAT, Vanderson ROCHA, Per LJUNGMAN, Ibrahim YAKOUB-AGHA, Nicolaus KROGER a Yves CHALANDON. Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party. \textit{Biology of Blood and Marrow Transplantation}. New York: Elsevier Science INC, 2019, roč.~25, č.~10, s.~2008-2016. ISSN~1083-8791. Dostupné z: https://dx.doi.org/10.1016/j.bbmt.2019.06.028.

Podrobný výpis o publikaci